The Next Generation of Investors
Ocugen Inc (NASDAQ: OCGN) is a US based bio-pharma which has primarily focused its research on developing a cure for blindness disease. In 2020, Ocugen shifted its efforts to distribute a COVID-19 vaccine with Indian partner Bharat Biotech. Ocugen’s CEO Shankar Musunuri made it clear that the company strategises to disrupt the current COVID-19 vaccine market with Covaxin.…
Soaring Eagle Acquisition Corp. (NASDAQ:SRNG) is set to merge with bio tech company Ginkgo Bioworks in a $15 Billion deal. The mammoth deal is expected to provide the biotech company $2.5 Billion in primary cash proceeds to fund future growth within multiple industries.…
To say Moderna (NASDAQ:MRNA) has had a brilliant year trading on Wallstreet would be an understatement. The COVID-19 vaccine candidate has provided investors immense returns over the past 12-18 months gaining 333% YTD.
Moderna’s strong revenue boost in 2021 has been derived from the overall depth of the COVID-19 vaccine market, which is expected to grow to $132.3 billion by 2025.…
Ocugen Inc (NASDAQ: OCGN) has been given a boost from Wallstreet this morning after Noble Financial analyst Robert LeBoyer initiated coverage with a Buy rating and a $15 price target. The price target suggests an upside of 114% from the current trading price.…
Cassava Sciences Inc (NASDAQ:SAVA) stock has experienced a strong bullish run over the past month, gaining 51%. Investors are awaiting Cassava’s clinical-trial data to be presented at the Alzheimer’s Association International Conference (AAIC) on July 29. The data is from Cassava’s leading candidate Sumifilam.…
Tempest Therapeutics (NASDAQ:TPST) is gaining momentum this week after H.C Wainwright listed a $51 price target on the stock. The stock is running strong after the completion of the Millendo Therapeutics merger. TPST has gained 108% over the past week of trading, which is driving large amounts of interest in the stock.…
Clover Health Investments Corp (NASDAQ: CLOV) has struggled over the past month, declining by 33%. Despite the recent decline, Clover is the fastest growing Medicare Advantage insurer in the United States. The company serves more than 66,300 members all in the United States.…
Ocugen Inc (NASDAQ: OCGN) is a US based bio-pharma which has focused on developing a cure for blindness disease. However, the company has since shifted its efforts to develop a COVID-19 vaccine with partner Bharat Biotech. Ocugen’s CEO Shankar Musunuri has made it clear the company strategises to disrupt the current COVID-19 vaccine market with Covaxin.…
Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of Wallstreet after the company obtained authorisation to commence Phase 2 trials for its COVID-19 experimental treatment COVI-DROPS. COVIDROPS is a intranasal formulation of Sorrento’s COVI-AMG™ neutralizing antibody that aims to boost immunity by blocking the infection and spread of the virus.…
Novavax, Inc.(NASDAQ: NVAX) has seen an incredible year in stock price growth, increasing 307% over the past 12 months. The companies COVID-19 vaccine saw the market rally behind NVAX, posting a 52 week high in February of $331.68. The company announced yesterday that their COVID-19 vaccine NVX-CoV2373 demonstrated 100% protection against moderate and severe disease and a 90.4% efficacy overall in the Phase 3 trial.…
Vaxart Inc (NASDAQ: VXRT) stock has seen a recent spike in investor confidence, gaining 23.81% over the past week. Vaxart has developed an oral vaccine for COVID-19 which has vastly differentiated itself from the competition. A recent study by Quadrant Strategies has shown that one third of people refusing to be vaccinated for COVID-19, would take an oral vaccine as an alternative to an injection.…
Longterm shareholders of Biogen (NASDAQ:BIIB) rejoice today after the company received accelerated approval from the FDA for their Alzheimer’s treatment ADUHELM™. The approval marks a historic day as ADUHELM becomes the first treatment to receive approval that addresses an underlying pathology of the disease.…
BioNano Genomics Inc (NASDAQ: BNGO) has had a remarkable year of trading, gaining over 979% over the past two months. The company operates in the analytical instruments field, in particular cytogenomics. Simply put, this is the detection of genetic disorders by analyzing the variances in chromosomes.…
Vaxart Inc (NASDAQ: VXRT) has seen a remarkable year on Wallstreet after investors rallied behind its experimental COVID-19 vaccine. VXRT stock has gained some serious ground over the past year, surging over 1,559% YTD. Unlike other COVID-19 vaccine candidates, the vaccine is administered orally and can be stored at room temperature.…
Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of investors as analysts remain confident in the companies 12 month outlook. The stock has performed well as of late, posting a 29% gain over the past month of trading. Furthermore, the average 12 month price target amongst Wallstreet analysts is $29.67 a share.…
Social Capital Hedosophia (NYSE: IPOC) are set to close in on their merger with Clover Health in early 2021. Evidently, this has caused a strong upswing in investor momentum in IPOC’s trading price. IPOC has gained 33% over the past week of trading and 66% for the month of December.…
The past two weeks have seen a large shift in investor sentiment towards these two key COVID vaccine pioneers. Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) have seen a recent surge in the share price. The companies saw an increase of 26.52% (NVAX) and 38.26% (MRNA) respectively over the past week of trading.…
iBio inc. (NYSE:IBIO) rose to popularity amongst the investor community as they announced their intentions to develop a COVID-19 vaccine. The stock is currently trading 586% higher since the beginning of 2020. However since July, iBio stock has been on a downward slope which has since found a new equilibrium at $2.…
Sorrento Therapeutics (NASDAQ: SRNE) was lacking direction as short-sellers brought down the stock after most positive announcements. However, the green light from the FDA allows the bulls to lay down the trackwork. The clear path is promising, but the volatility is making it difficult for investors to enter.…
CVS Health (NASDAQ: CVS) stock has been going on a rollercoaster ride in 2020 so far. The start of the year was promising as the healthcare giant hit 52-week highs. Unfortunately, COVID-19 sent CVS spiraling down. Investors are currently unsure what is in store for CVS come 2021 and beyond.…